Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 101,643
  • Shares Outstanding, K 41,657
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,123 K
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.24
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.14
  • Most Recent Earnings -0.17 on 06/30/20
  • Next Earnings Date 11/10/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +624,475.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +17.50%
on 09/04/20
2.52 -6.75%
on 09/18/20
+0.15 (+6.82%)
since 08/21/20
3-Month
2.00 +17.50%
on 09/04/20
2.99 -21.40%
on 07/23/20
-0.27 (-10.31%)
since 06/22/20
52-Week
0.48 +389.58%
on 10/02/19
7.84 -70.03%
on 12/31/19
+1.40 (+147.37%)
since 09/20/19

Most Recent Stories

More News
Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September:

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences

SAN DIEGO and CALGARY, Alberta , Sept. 1, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview...

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
Stocks in play: Oncolytics Biotech® Inc.

Announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of ...

ONC.TO : 2.35 (-3.69%)
Stepped Up Clinical Efforts Targeting Breast Cancer Therapies and Treatments Leading to Opportunistic Options

, /PRNewswire/ -- Although various market revenue projections may differ in the total dollar figures, the reports in the triple negative breast cancer (TNBC) treatment market all predict a sustainable...

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
ORTX : 4.91 (+0.41%)
HTBX : 1.4100 (+1.44%)
SRPT : 146.31 (+2.43%)
BMY : 58.76 (+1.71%)
Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

and , /PRNewswire/ --  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1...

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

- Expansion of Oncolytics' lead breast cancer program into a new disease subtype

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
ONCWF : 0.0350 (-0.85%)
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

, /PRNewswire/ --   – In the fight against some of the most challenging forms of cancer, (NYSE:AZN) recently placed a giant  on an antibody-drug conjugate (ADC) called DS-1062 from Japanese developers...

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
MRK : 82.94 (-0.23%)
IMMU : 85.05 (-0.42%)
AZN : 55.44 (-0.84%)
PFE : 36.25 (+0.64%)
Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently ...

AZN : 55.44 (-0.84%)
IMMU : 85.05 (-0.42%)
PFE : 36.25 (+0.64%)
MRK : 82.94 (-0.23%)
ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the Canaccord Genuity 40 Annual Growth Conference....

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference

SAN DIEGO, Calif. and CALGARY, AB , Aug. 10, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside...

ONCY : 1.7600 (-4.61%)
ONC.TO : 2.35 (-3.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 2.54
1st Resistance Point 2.44
Last Price 2.35
1st Support Level 2.28
2nd Support Level 2.22

See More

52-Week High 7.84
Fibonacci 61.8% 5.03
Fibonacci 50% 4.16
Fibonacci 38.2% 3.29
Last Price 2.35
52-Week Low 0.48

See More

Business Summary

Oncolytics Biotech Inc is a development stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar